Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2021 Apr;25(26):1–76. doi: 10.3310/hta25260

Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT.

Ian Roberts, Haleema Shakur-Still, Amy Aeron-Thomas, Danielle Beaumont, Antonio Belli, Amy Brenner, Madeleine Cargill, Rizwana Chaudhri, Nicolas Douglas, Lauren Frimley, Catherine Gilliam, Amber Geer, Zahra Jamal, Rashid Jooma, Raoul Mansukhani, Alec Miners, Jason Pott, Danielle Prowse, Temitayo Shokunbi, Jack Williams
PMCID: PMC8107835  PMID: 33928903

Abstract

BACKGROUND

Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death. We assessed the effects of tranexamic acid in traumatic brain injury patients.

OBJECTIVE

To assess the effects of tranexamic acid on death, disability and vascular occlusive events in traumatic brain injury patients. We also assessed cost-effectiveness.

DESIGN

Randomised trial and economic evaluation. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation. All analyses were by intention to treat. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a UK NHS perspective using the trial results and a Markov model.

SETTING

175 hospitals in 29 countries.

PARTICIPANTS

Adults with traumatic brain injury within 3 hours of injury with a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no major extracranial bleeding, were eligible.

INTERVENTION

Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo.

MAIN OUTCOME MEASURES

Head injury death in hospital within 28 days of injury in patients treated within 3 hours of injury. Secondary outcomes were early head injury deaths, all-cause and cause-specific mortality, disability, vascular occlusive events, seizures, complications and adverse events.

RESULTS

Among patients treated within 3 hours of injury (n = 9127), the risk of head injury death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855/4613 vs. 892/4514; risk ratio 0.94, 95% confidence interval 0.86 to 1.02). In a prespecified analysis excluding patients with a Glasgow Coma Scale score of 3 or bilateral unreactive pupils at baseline, the results were 12.5% in the tranexamic acid group versus 14.0% in the placebo group (485/3880 vs. 525/3757; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head injury (166/2846 vs. 207/2769; risk ratio 0.78, 95% confidence interval 0.64 to 0.95), but in those with severe head injury (689/1739 vs. 685/1710; risk ratio 0.99, 95% confidence interval 0.91 to 1.07) there was no apparent reduction (p-value for heterogeneity = 0.030). Early treatment was more effective in mild and moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in cases of severe head injury (p = 0.73). The risk of disability, vascular occlusive events and seizures was similar in both groups. Tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury (base case of £4288 per quality-adjusted life-year gained).

CONCLUSION

Early tranexamic acid treatment reduces head injury deaths. Treatment is cost-effective for patients with mild or moderate traumatic brain injury, or those with both pupils reactive.

FUTURE WORK

Further trials should examine early tranexamic acid treatment in mild head injury. Research on alternative routes of administration is needed.

LIMITATIONS

Time to treatment may have been underestimated.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN15088122, ClinicalTrials.gov NCT01402882, EudraCT 2011-003669-14, Pan African Clinical Trial Registry PACTR20121000441277.

FUNDING

The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26. See the NIHR Journals Library website for further project information. In addition, funding was provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for International Development and the Wellcome Trust). This project was funded by the NIHR Global Health Trials programme.

Plain language summary

Traumatic brain injury is a leading cause of death and disability worldwide, with over 60 million new cases each year. When the head is injured there is often bleeding inside the brain, which can continue for some time and worsen after hospital admission. This bleeding increases pressure inside the skull, causing further damage to the brain, which can be fatal or result in serious disability. Tranexamic acid is a cheap drug that reduces bleeding in other conditions. A large trial of accident victims (other than those with head injury) found that it reduced the chances of bleeding to death. We wanted to find out if tranexamic acid would also reduce deaths among patients with head injuries. We studied just under 13,000 patients with traumatic brain injury who did not have other major injuries to their bodies from 175 hospitals across 29 countries. Patients were assigned at random to receive either tranexamic acid or a dummy medicine called a placebo. Neither the clinical team nor the patient knew which medicine the patient received. All patients received the usual treatments given to head-injured patients. Outcomes from 9127 participants were analysed. Among patients treated early, within 3 hours, the rate of head injury death was 18.5% (855/4613) in the tranexamic acid group and 19.8% (892/4514) in the placebo group. We found no evidence of an effect of tranexamic acid overall. However, in patients with mild or moderate traumatic brain injury, there was a 20% reduction in deaths. There were no side effects and no increase in disability in survivors when the drug was used. The economic analysis shows that tranexamic acid represents value for money for patients with mild or moderate traumatic brain injury.

Full text of this article can be found in Bookshelf.

References

  1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg 2018;1:1–18. https://doi.org/10.3171/2017.10.JNS17352 doi: 10.3171/2017.10.JNS17352. [DOI] [PubMed]
  2. Peden N, Scurfield R, Sleet D, Mohan D, Hyder AA, Jarawan E, Mathers C. World Report on Road Traffic Injury Prevention. Geneva: World Health Organization; 2004.
  3. Haydel M. Assessment of Traumatic Brain Injury, Acute. BMJ Best Practice; 2018. URL: https://bestpractice.bmj.com/topics/en-gb/515 (accessed 28 November 2019).
  4. Perel P, Roberts I, Bouamra O, Woodford M, Mooney J, Lecky F. Intracranial bleeding in patients with traumatic brain injury: a prognostic study. BMC Emerg Med 2009;9:15. https://doi.org/10.1186/1471-227X-9-15 doi: 10.1186/1471-227X-9-15. [DOI] [PMC free article] [PubMed]
  5. Oertel M, Kelly DF, McArthur D, Boscardin WJ, Glenn TC, Lee JH, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002;96:109–16. https://doi.org/10.3171/jns.2002.96.1.0109 doi: 10.3171/jns.2002.96.1.0109. [DOI] [PubMed]
  6. Narayan RK, Maas AI, Servadei F, Skolnick BE, Tillinger MN, Marshall LF, Traumatic Intracerebral Hemorrhage Study Group. Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma 2008;25:629–39. https://doi.org/10.1089/neu.2007.0385 doi: 10.1089/neu.2007.0385. [DOI] [PubMed]
  7. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005;365:1957–9. https://doi.org/10.1016/S0140-6736(05)66552-X doi: 10.1016/S0140-6736(05)66552-X. [DOI] [PubMed]
  8. Rodríguez-Boto G, Rivero-Garvía M, Gutiérrez-González R, Márquez-Rivas J. Basic concepts about brain pathophysiology and intracranial pressure monitoring. Neurologia 2015;30:16–22. https://doi.org/10.1016/j.nrl.2012.09.002 doi: 10.1016/j.nrl.2012.09.002. [DOI] [PubMed]
  9. Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017;80:6–15. https://doi.org/10.1227/NEU.0000000000001432 doi: 10.1227/NEU.0000000000001432. [DOI] [PubMed]
  10. Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien) 2008;150:165–75. https://doi.org/10.1007/s00701-007-1475-8 doi: 10.1007/s00701-007-1475-8. [DOI] [PubMed]
  11. Bayir A, Kalkan E, Koçak S, Ak A, Cander B, Bodur S. Fibrinolytic markers and neurologic outcome in traumatic brain injury. Neurol India 2006;54:363–5. https://doi.org/10.4103/0028-3886.28106 doi: 10.4103/0028-3886.28106. [DOI] [PubMed]
  12. Gebel JM, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, et al. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2636–41. https://doi.org/10.1161/01.str.0000035283.34109.ea doi: 10.1161/01.str.0000035283.34109.ea. [DOI] [PubMed]
  13. Figueroa BE, Keep RF, Betz AL, Hoff JT. Plasminogen activators potentiate thrombin-induced brain injury. Stroke 1998;29:1202–7. https://doi.org/10.1161/01.str.29.6.1202 doi: 10.1161/01.str.29.6.1202. [DOI] [PubMed]
  14. Thiex R, Küker W, Müller HD, Rohde I, Schröder JM, Gilsbach JM, Rohde V. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol Res 2003;25:254–62. https://doi.org/10.1179/016164103101201463 doi: 10.1179/016164103101201463. [DOI] [PubMed]
  15. Thiex R, Mayfrank L, Rohde V, Gilsbach JM, Tsirka SA. The role of endogenous versus exogenous tPA on edema formation in murine ICH. Exp Neurol 2004;189:25–32. https://doi.org/10.1016/j.expneurol.2004.05.021 doi: 10.1016/j.expneurol.2004.05.021. [DOI] [PubMed]
  16. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011;1:CD001886. https://doi.org/10.1002/14651858.CD001886.pub3 doi: 10.1002/14651858.CD001886.pub3. [DOI] [PubMed]
  17. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32. https://doi.org/10.1016/S0140-6736(10)60835-5 doi: 10.1016/S0140-6736(10)60835-5. [DOI] [PubMed]
  18. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096–101, 1101.e1–2. https://doi.org/10.1016/S0140-6736(11)60278-X doi: 10.1016/S0140-6736(11)60278-X. [DOI] [PubMed]
  19. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet 2018;391:125–32. https://doi.org/10.1016/S0140-6736(17)32455-8 doi: 10.1016/S0140-6736(17)32455-8. [DOI] [PMC free article] [PubMed]
  20. Crash-2 Collaborators (Intracranial Bleeding Study). Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011;343:d3795. https://doi.org/10.1136/bmj.d3795 doi: 10.1136/bmj.d3795. [DOI] [PMC free article] [PubMed]
  21. Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, Thinkamrop B, Phuenpathom N, Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013;13:20. https://doi.org/10.1186/1471-227X-13-20 doi: 10.1186/1471-227X-13-20. [DOI] [PMC free article] [PubMed]
  22. Dewan Y, Komolafe EO, Mejía-Mantilla JH, Perel P, Roberts I, Shakur H, CRASH-3 Collaborators. CRASH-3 – tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012;13:87. https://doi.org/10.1186/1745-6215-13-87 doi: 10.1186/1745-6215-13-87. [DOI] [PMC free article] [PubMed]
  23. Roberts I, Belli A, Brenner A, Chaudhri R, Fawole B, Harris T. Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Wellcome Open Res 2018;3:86 https://doi.org/10.12688/wellcomeopenres.14700.2 doi: 10.12688/wellcomeopenres.14700.2. [DOI] [PMC free article] [PubMed]
  24. The CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019:394;1713–23. https://doi.org/10.1016/S0140-6736(19)32233-0 doi: 10.1016/S0140-6736(19)32233-0. [DOI] [PMC free article] [PubMed]
  25. Weijer C, Shapiro SH, Cranley Glass K. For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ 2000;321:756–8. https://doi.org/10.1136/bmj.321.7263.756 doi: 10.1136/bmj.321.7263.756. [DOI] [PMC free article] [PubMed]
  26. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053 doi: 10.1001/jama.2013.281053. [DOI] [PubMed]
  27. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose–response relationship of tranexamic acid. Anesthesiology 1995;82:383–92. https://doi.org/10.1097/00000542-199502000-00009 doi: 10.1097/00000542-199502000-00009. [DOI] [PubMed]
  28. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head trauma: coma to community. Arch Phys Med Rehabil 1982;63:118–23. https://doi.org/10.1037/t29015-000 doi: 10.1037/t29015-000. [DOI] [PubMed]
  29. Electronic Medicines Compendium. Tranexamic Acid 100 mg/ml Solution for Injection. 2018. URL: www.medicines.org.uk/emc/product/1220/smpc#gref (accessed 28 November 2019).
  30. Hijazi N, Abu Fanne R, Abramovitch R, Yarovoi S, Higazi M, Abdeen S, et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 2015;125:2558–67. https://doi.org/10.1182/blood-2014-08-588442 doi: 10.1182/blood-2014-08-588442. [DOI] [PMC free article] [PubMed]
  31. Medcalf RL. The traumatic side of fibrinolysis. Blood 2015;125:2457–8. https://doi.org/10.1182/blood-2015-02-629808 doi: 10.1182/blood-2015-02-629808. [DOI] [PubMed]
  32. Barton BL. International conference on harmonization-good clinical practices update. Drug Inf J 1998;32:1143–7. https://doi.org/10.1177/00928615980320043410 doi: 10.1177/00928615980320043410. [DOI]
  33. Chapman MP, Moore EE, Moore HB, Gonzalez E, Gamboni F, Chandleret JG, et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016;80:16–23. https://doi.org/10.1097/TA.0000000000000885 doi: 10.1097/TA.0000000000000885. [DOI] [PMC free article] [PubMed]
  34. Wu X, Darlington DN, Cap AP. Procoagulant and fibrinolytic activity after polytrauma in rat. Am J Physiol Regul Integr Comp Physiol 2016;310:R323–9. https://doi.org/10.1152/ajpregu.00401.2015 doi: 10.1152/ajpregu.00401.2015. [DOI] [PMC free article] [PubMed]
  35. Roberts I, Prieto-Merino D, Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care 2014;18:685. https://doi.org/10.1186/s13054-014-0685-8 doi: 10.1186/s13054-014-0685-8. [DOI] [PMC free article] [PubMed]
  36. Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, et al. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015;78(Suppl. 6):65–9. https://doi.org/10.1097/TA.0000000000000634 doi: 10.1097/TA.0000000000000634. [DOI] [PMC free article] [PubMed]
  37. Epstein DS, Mitra B, O’Reilly G, Rosenfeld JV, Cameron PA. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: a systematic review and meta-analysis. Injury 2014;45:819–24. https://doi.org/10.1016/j.injury.2014.01.011 doi: 10.1016/j.injury.2014.01.011. [DOI] [PubMed]
  38. Abdelmalik PA, Boorman DW, Tracy J, Jallo J, Rincon F. Acute traumatic coagulopathy accompanying isolated traumatic brain injury is associated with worse long-term functional and cognitive outcomes. Neurocrit Care 2016;24:361–70. https://doi.org/10.1007/s12028-015-0191-0 doi: 10.1007/s12028-015-0191-0. [DOI] [PubMed]
  39. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004;364:1321–8. https://doi.org/10.1016/S0140-6736(04)17188-2 doi: 10.1016/S0140-6736(04)17188-2. [DOI] [PubMed]
  40. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013 (PMG9). London: NICE; 2013. [PubMed]
  41. Williams J, Roberts I, Shakur-Still H, Lecky FE, Chaudhri R, Miners A. Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach. BMJ Global Health 2020;5:e002716. https://doi.org/10.1136/bmjgh-2020-002716 doi: 10.1136/bmjgh-2020-002716. [DOI] [PMC free article] [PubMed]
  42. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049. https://doi.org/10.1046/j.1365-2958.2001.02411.x doi: 10.1046/j.1365-2958.2001.02411.x. [DOI] [PubMed]
  43. McMillan TM, Teasdale GM, Weir CJ, Stewart E. Death after head injury: the 13 year outcome of a case control study. J Neurol Neurosurg Psychiatry 2011;82:931–5. https://doi.org/10.1136/jnnp.2010.222232 doi: 10.1136/jnnp.2010.222232. [DOI] [PubMed]
  44. Office for National Statistics. National Life Tables: UK. 2016–2018. 2019. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables (accessed 30 October 2019).
  45. Ward Fuller G, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the Glasgow Outcome Scale following traumatic brain injury: a systematic review and mapping study. Value Health 2017;20:141–51. https://doi.org/10.1016/j.jval.2016.09.2398 doi: 10.1016/j.jval.2016.09.2398. [DOI] [PMC free article] [PubMed]
  46. Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol 2014;13:844–54. https://doi.org/10.1016/S1474-4422(14)70120-6 doi: 10.1016/S1474-4422(14)70120-6. [DOI] [PubMed]
  47. Born K, Amsler F, Gross T. Prospective evaluation of the Quality of Life after Brain Injury (QOLIBRI) score: minor differences in patients with major versus no or mild traumatic brain injury at one-year follow up. Health Qual Life Outcomes 2018;16:136. https://doi.org/10.1186/s12955-018-0966-z doi: 10.1186/s12955-018-0966-z. [DOI] [PMC free article] [PubMed]
  48. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York: Centre for Health Economics, University of York; 1999.
  49. Joint Formulary Committee. British National Formulary. Sodium Chloride. Ed 77. London: BMJ Group and Pharmaceutical Press; 2019.
  50. National Institute for Health and Care Excellence (NICE). Costing Statement: Needle and Syringe Programmes. London: NICE; 2014.
  51. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I, CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLOS ONE 2011;6:e18987. https://doi.org/10.1371/journal.pone.0018987 doi: 10.1371/journal.pone.0018987. [DOI] [PMC free article] [PubMed]
  52. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social Services Research Unit, University of Kent; 2018.
  53. Department of Health and Social Care (DHSC). NHS Reference Costs 2017–18. London: DHSC; 2018.
  54. Beecham J, Perkins M, Snell T, Knapp M. Treatment paths and costs for young adults with acquired brain injury in the United Kingdom. Brain Inj 2009;23:30–8. https://doi.org/10.1080/02699050802590338 doi: 10.1080/02699050802590338. [DOI] [PubMed]
  55. Lecky F, Russell W, Fuller G, McClelland G, Pennington E, Goodacre S, et al. The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study. Health Technol Assess 2016;20(1). https://doi.org/10.3310/hta20010 doi: 10.3310/hta20010. [DOI] [PMC free article] [PubMed]
  56. Joint Formulary Committee. British National Formulary (online). Tranexamic Acid. London: BMJ Group and Pharmaceutical Press. URL: https://bnf.nice.org.uk/medicinal-forms/tranexamic-acid.html; 2019 (accessed 24 September 2019).
  57. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: https://bnf.nice.org.uk/medicinal-forms/sodium-chloride.html; 2019 (accessed 24 September 2019).
  58. May S. Prehospital Tranexamic Acid Use for Traumatic Brain Injury (TXA). URL: https://clinicaltrials.gov/ct2/show/ NCT01990768 (accessed 19 November 2019).
  59. Rodgers A, MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Thromb Haemost 1995;73:167–71. https://doi.org/10.1055/s-0038-1653746 doi: 10.1055/s-0038-1653746. [DOI] [PubMed]
  60. National Institute for Health and Care Excellence (NICE). Trauma Quality Standard (QS166). London: NICE; 2018.
  61. Mahmood A, Roberts I, Shakur H, Harris T, Belli A. Does tranexamic acid improve outcomes in traumatic brain injury? BMJ 2016;354:i4814. https://doi.org/10.1136/bmj.i4814 doi: 10.1136/bmj.i4814. [DOI] [PubMed]
  62. Perel P, Al-Shahi Salman R, Kawahara T, Morris Z, Prieto-Merino D. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury – a nested randomised, placebo-controlled trial. Health Technol Assess 2012;16(13). https://doi.org/10.3310/hta16130 doi: 10.3310/hta16130. [DOI] [PubMed]
  63. Joint Royal Colleges Ambulance Liaison Committee, Association of Ambulance Chief Executives. JRCALC Clinical Guidelines 2019. Bridgwater: Class Professional Publishing; 2019.
  64. National Institute for Health and Care Excellence (NICE). Head Injury: Assessment and Early Management. London: NICE; 2019. [PubMed]
  65. Coats TJ, Fragoso-Iñiguez M, Roberts I. Implementation of tranexamic acid for bleeding trauma patients: a longitudinal and cross-sectional study. Emerg Med J 2019;36:78–81. https://doi.org/10.1136/emermed-2018-207693 doi: 10.1136/emermed-2018-207693. [DOI] [PubMed]
  66. Wright C. Battlefield administration of tranexamic acid by combat troops: a feasibility analysis. J R Army Med Corps 2014;160:271–2. https://doi.org/10.1136/jramc-2013-000152 doi: 10.1136/jramc-2013-000152. [DOI] [PubMed]
  67. Carley S, Mackway-Jones K, Donnan S. Major incidents in Britain over the past 28 years: the case for the centralised reporting of major incidents. J Epidemiol Community Health 1998;52:392–8. https://doi.org/10.1136/jech.52.6.392 doi: 10.1136/jech.52.6.392. [DOI] [PMC free article] [PubMed]
  68. Puigdellívol E, Carral ME, Moreno J, Plà-Delfina JM, Jané F. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol 1985;23:298–301. [PubMed]
  69. Sano M, Hakusui H, Kojima C, Akimoto T. Absorption and excretion of tranexamic acid following intravenous, intramuscular and oral administrations in healthy volunteers. Rinsho yakuri/Japanese J Clin Pharmacol Ther 1976;7:375–82. https://doi.org/10.3999/jscpt.7.375 doi: 10.3999/jscpt.7.375. [DOI]
  70. Haljamäe H. Microcirculation and hemorrhagic shock. Am J Emerg Med 1984;2:100–7. https://doi.org/10.1016/0735-6757(84)90117-7 doi: 10.1016/0735-6757(84)90117-7. [DOI] [PubMed]
  71. Yost J, Baldwin P, Bellenger S, Bradshaw F, Causapin E, Demotica R, et al. The pharmacokinetics of intraosseous atropine in hypovolemic swine. Am J Disaster Med 2015;10:217–22. https://doi.org/10.5055/ajdm.2015.0204 doi: 10.5055/ajdm.2015.0204. [DOI] [PubMed]
  72. First Release of CRASH-3 Trial Results. Conference Presentation. Presented by Ian Roberts. World Congress of Intensive Care 2019, Melbourne, VIC, 15 October 2019.
  73. Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-controlled Trial. Conference Presentation. Presented by Haleema Shakur-Still 17th Annual Meeting Neurocritical Care Society, Vancouver, BC, 16 October 2019. doi: 10.1016/S0140-6736(19)32233-0. [DOI] [PMC free article] [PubMed]
  74. World Health Organization (WHO). WHO Model List of Essential Medicines. Geneva: WHO; 2019.
  75. Guthrie S, Hafner M, Bienkowska-Gibbs T, Wooding S. Returns on research funded under the NIHR Health Technology Assessment (HTA) programme. Rand Health Q 2016;5:5. [PMC free article] [PubMed]
  76. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 2012;147:113–19. https://doi.org/10.1001/archsurg.2011.287 doi: 10.1001/archsurg.2011.287. [DOI] [PubMed]
  77. European Council. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. 2001. URL: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (accessed 20 November 2020).
  78. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008;336:425–9. https://doi.org/10.1136/bmj.39461.643438.25 doi: 10.1136/bmj.39461.643438.25. [DOI] [PMC free article] [PubMed]

RESOURCES